Uncategorized

The general manager for the business says building a market is something the medtech giant knows how to do.

According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

CEO Ivan Tornos said multiple factors emerged late in the quarter that caused the shortfall. Zimmer’s shares plunged more than 15%.

Prospect Medical Holdings is seeking approval from a bankruptcy court to close its hospitals in Rhode Island. Regulators and the new buyer say Prospect needs to follow through with a deal to sell them.

The company is considering selling assets that could be more easily separated from the rest of the business without creating challenges for customers, executives said on a third quarter earnings call. 

Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.

Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug failed to significantly improve social avoidance in a late-stage study in fragile X Syndrome.

Arena launched with $500 million in early 2024 to fund basic biological research, from which it planned to spin out dedicated companies to focus on drug development.